Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis

Fan Liu(University of Miami), Guoyan Cheng(Sylvester Comprehensive Cancer Center), Pierre-Jacques Hamard(Sylvester Comprehensive Cancer Center), Sarah Greenblatt(Sylvester Comprehensive Cancer Center), Lan Wang(Sylvester Comprehensive Cancer Center), Na Man(Sylvester Comprehensive Cancer Center), Fabiana Perna, Haiming Xu, Madhavi Tadi(University of Miami), Luisa Luciani(Sylvester Comprehensive Cancer Center), Stephen D. Nimer(Sylvester Comprehensive Cancer Center)
Journal of Clinical Investigation
August 10, 2015
Cited by 150Open Access
Full Text

Abstract

Epigenetic regulators play critical roles in normal hematopoiesis, and the activity of these enzymes is frequently altered in hematopoietic cancers. The major type II protein arginine methyltransferase PRMT5 catalyzes the formation of symmetric dimethyl arginine and has been implicated in various cellular processes, including pluripotency and tumorigenesis. Here, we generated Prmt5 conditional KO mice to evaluate the contribution of PRMT5 to adult hematopoiesis. Loss of PRMT5 triggered an initial but transient expansion of hematopoietic stem cells (HSCs); however, Prmt5 deletion resulted in a concurrent loss of hematopoietic progenitor cells (HPCs), leading to fatal BM aplasia. PRMT5-specific effects on hematopoiesis were cell intrinsic and depended on PRMT5 methyltransferase activity. We found that PRMT5-deficient hematopoietic stem and progenitor cells exhibited severely impaired cytokine signaling as well as upregulation of p53 and expression of its downstream targets. Together, our results demonstrate that PRMT5 plays distinct roles in the behavior of HSCs compared with HPCs and is essential for the maintenance of adult hematopoietic cells.


Related Papers

No related papers found

Powered by citation graph analysis